Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

This study has been terminated.

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00000809

Purpose

The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.

Condition	Intervention	Phase
HIV Infections HIV Seronegativity	Biological: Aluminum hydroxide Biological: QS-21 Biological: MN rsgp120/HIV-1	Phase I

Study Type:	Interventional
Study Design:	Prevention, Dose Comparison
Official Title:	A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Aluminum hydroxide QS 21 Algeldrate Aluminum

U.S. FDA Resources

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	up to 3 Days
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria

Infants may be eligible for this study if they:

Are 1 to 3 days old.

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Study ID Numbers:	ACTG 279
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000809 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

HIV Preventive Vaccine
HIV Therapeutic Vaccine

Study placed in the following topic categories:

Sexually Transmitted Diseases, Viral
Immunologic Factors
Acquired Immunodeficiency Syndrome
Adjuvants, Immunologic
Immunologic Deficiency Syndromes
Aluminum Hydroxide
Virus Diseases

Aluminum sulfate
HIV Infections
Sexually Transmitted Diseases
Antacids
QS 21
Retroviridae Infections

Additional relevant MeSH terms:

RNA Virus Infections
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Immune System Diseases
Physiological Effects of Drugs
Acquired Immunodeficiency Syndrome
Adjuvants, Immunologic
Infection

Pharmacologic Actions
Immunologic Deficiency Syndromes
Aluminum Hydroxide
Virus Diseases
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections
Antacids
Retroviridae Infections

ClinicalTrials.gov processed this record on July 02, 2009